8-K: Intellia Reports Strong Longer-Term Phase 1 Nex-z Data

Intellia Therapeutics announced positive longer-term Phase 1 data for its gene editing therapy, nexiguran ziclumeran (nex-z), showing deep and durable TTR reductions and clinical improvements in ATTRv-PN patients.

Summary

• Intellia Therapeutics announced positive longer-term follow-up data from its ongoing Phase 1 study of nexiguran ziclumeran (nex-z) for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).
• A single dose of nex-z led to rapid, deep, and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three years.
• At 24 months, patients receiving 0.3 mg/kg or higher (n=33) showed a mean serum TTR reduction of 92%, corresponding to a mean absolute serum TTR level of 17.3 g/mL (95% CI, 12.5 – 22.2).
• Among 12 patients reaching 36 months, the mean serum TTR reduction was 90%, with a mean absolute serum TTR level of 20 g/mL (95% CI, 11.2 – 28.8).
• Favorable trends indicating stability or improvement were observed in most ATTRv-PN patients across multiple clinical and biomarker measures, including NIS, mNIS+7, mBMI, QoL-DN, NfL, and PND score.
• 72% (13 of 18) of patients with a 24-month mNIS+7 assessment showed clinically meaningful improvements of 4 points or more, including most of the patients who had progressed on patisiran.
• 89% of patients demonstrated improvement or stability in PND scores through 24 months compared to baseline.
• Nex-z was generally well tolerated, with infusion-related reactions being the most common mild or moderate treatment-related adverse events, none leading to discontinuations.
• Three participants previously reported Grade 3 liver enzyme elevations, which were asymptomatic, resolved spontaneously, and were not considered serious.
• The Phase 3 MAGNITUDE-2 trial, evaluating nex-z in approximately 50 ATTRv-PN patients, began dosing in April 2025, with enrollment expected to complete in the first half of 2026.
• Intellia anticipates submitting a biologics license application (BLA) for ATTRv-PN by 2028.

Sentiment

Score: 9

Explanation: The filing presents exceptionally strong longer-term Phase 1 data for nex-z, demonstrating deep, durable TTR reductions and significant clinical improvements in a high percentage of patients. The safety profile remains favorable, and the Phase 3 trial is progressing rapidly towards a BLA submission. This indicates a highly positive outlook for the drug and the company's gene editing platform.

Positives

• Deep, durable, and consistent TTR reductions were observed, with a mean 92% reduction at 24 months and 90% at 36 months in patients receiving 0.3 mg/kg or higher doses.
• 72% of patients (13 out of 18 assessed) showed clinically meaningful improvements of 4 points or more in mNIS+7 at 24 months, including most of those who had progressed on patisiran.
• 89% of patients demonstrated improvement or stability in PND scores through 24 months compared to baseline.
• Mean values of secondary endpoints like mBMI, QoL-DN, and NfL all trended toward disease improvement.
• Nex-z was generally well tolerated, with no new drug-related adverse events reported within the follow-up period and no discontinuations due to infusion-related reactions.
• The Phase 3 MAGNITUDE-2 trial is advancing rapidly, with dosing initiated in April 2025 and enrollment expected to complete in the first half of 2026.

Risks

• Risks related to Intellia's ability to protect and maintain its intellectual property position.
• Risks related to valid third-party intellectual property.
• Risks related to Intellia's relationships with third parties, including its licensors and licensees.
• Risks related to the ability of its licensors to protect and maintain their intellectual property position.
• Uncertainties related to regulatory agencies' evaluation of regulatory filings and other information for product candidates, including nex-z.
• Uncertainties related to the authorization, initiation, and conduct of studies and other development requirements for product candidates, including regulatory approvals for clinical trials.
• The risk that any one or more of Intellia's product candidates, including nex-z, will not be successfully developed and commercialized.
• The risk that results of preclinical or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or other product candidates.
• Risks related to Intellia's reliance on collaborations, specifically that its collaboration with Regeneron Pharmaceuticals, Inc. may not continue or be successful.

Future Outlook

Intellia expects to complete enrollment in its global Phase 3 MAGNITUDE-2 study for ATTRv-PN in the first half of 2026 and anticipates submitting a biologics license application for nex-z for the treatment of ATTRv-PN by 2028. The company believes that a single dose of nex-z leads to deep, durable, and consistent reductions in serum TTR, and that increasingly deep reductions translate to better patient outcomes. Management is confident that the MAGNITUDE-2 trial will demonstrate nex-z's potential to halt or reverse disease progression in people living with ATTRv-PN.

Management Comments

• "After receiving a one-time treatment of nex-z, patients continue to experience durable TTR reductions, including those who have reached three years of follow-up."
• "The results from our ongoing Phase 1 study of nex-z support our belief that deeper and more consistent reductions in TTR translate to better outcomes for patients."
• "Our Phase 3 MAGNITUDE-2 study is progressing swiftly, and we are eagerly anticipating the results, which we believe will demonstrate nex-z's potential to halt or reverse disease progression in people living with ATTRv-PN."

Industry Context

The announcement highlights significant progress in the gene editing space, particularly for rare diseases like ATTR amyloidosis, where current treatments are limited to slowing disease progression. Nex-z, as a potential one-time CRISPR-based therapy, represents a disruptive innovation compared to existing chronic treatments. The positive longer-term data positions Intellia as a leader in developing curative gene editing solutions, potentially setting a new standard for ATTRv-PN treatment and validating the broader CRISPR platform for in vivo applications.

Comparison to Industry Standards

• Nex-z's sustained TTR reduction of 90-92% at 24-36 months is highly competitive, potentially surpassing the efficacy of existing TTR stabilizers (e.g., tafamidis) and RNAi therapies (e.g., patisiran, inotersen) which typically aim for significant but often less profound or durable reductions.
• The observation of clinical improvements in 72% of mNIS+7 assessed patients, including those who progressed on patisiran, suggests a potential for superior or more comprehensive disease modification compared to therapies that primarily slow progression.
• As a one-time treatment, nex-z offers a significant advantage over chronic therapies, potentially improving patient adherence and quality of life, a key differentiator in the rare disease market.
• The rapid advancement of the Phase 3 MAGNITUDE-2 trial, with enrollment expected in H1 2026, indicates a competitive development timeline for a gene editing therapy in a complex indication.

Stakeholder Impact

• Shareholders: Highly positive impact due to strong clinical data, validating the company's CRISPR platform and increasing the likelihood of successful commercialization for a significant market opportunity. Potential for increased share price.
• Patients with ATTRv-PN: Significant positive impact as nex-z offers the potential for a one-time, disease-modifying treatment that could halt or reverse progression, addressing a high unmet medical need.
• Medical Community: Provides strong evidence for the potential of in vivo gene editing therapies, potentially shifting treatment paradigms for ATTR amyloidosis and other genetic diseases.
• Regeneron Pharmaceuticals, Inc. (Collaboration Partner): Positive impact due to the successful advancement of a key collaborative program, reinforcing the value of their partnership with Intellia.

Next Steps

• Continue patient screening and enrollment in the Phase 3 MAGNITUDE-2 trial.
• Complete enrollment in the MAGNITUDE-2 trial in the first half of 2026.
• Submit a biologics license application (BLA) for nex-z for ATTRv-PN by 2028.
• Further evaluate the efficacy and safety of nex-z in the ongoing Phase 3 MAGNITUDE-2 trial.

Key Dates

Recommendation

The longer-term Phase 1 data for nexiguran ziclumeran is exceptionally strong, demonstrating deep, durable TTR reductions and clinically meaningful improvements in a high percentage of ATTRv-PN patients, including those who previously progressed on other therapies. The safety profile remains favorable. This data significantly de-risks the program and strengthens the probability of success for the ongoing Phase 3 trial and subsequent BLA submission. As a potential one-time gene editing therapy, nex-z represents a transformative treatment with a large market opportunity, positioning Intellia as a leader in the gene editing space. The rapid progress of the Phase 3 trial further supports a strong positive outlook.

Keywords

Intellia Therapeutics, NTLA, CRISPR, Gene Editing, Nexiguran Ziclumeran, nex-z, NTLA-2001, ATTR Amyloidosis, ATTRv-PN, Polyneuropathy, Phase 1 Clinical Trial, Phase 3 MAGNITUDE-2, TTR Reduction, Biologics License Application, Rare Disease, Clinical Data, Biotechnology, Pharmaceuticals